Krebs Biochemicals & Industries Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹63.32
- Today's High:
- ₹64.6
- Open Price:
- ₹64.6
- 52W Low:
- ₹51.1
- 52W High:
- ₹135
- Prev. Close:
- ₹64.6
- Volume:
- 1505
Company Statistics
- Market Cap.:
- ₹1.75 billion
- Book Value:
- Revenue TTM:
- ₹403.21 million
- Operating Margin TTM:
- -55.68%
- Gross Profit TTM:
- ₹948000
- Profit Margin:
- -69.46%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Krebs Biochemicals & Industries Limited had its IPO on under the ticker symbol 524518.
The company operates in the Other sector and Other industry. Krebs Biochemicals & Industries Limited has a staff strength of 374 employees.
Stock update
Shares of Krebs Biochemicals & Industries Limited opened at ₹64.6 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹63.32 - ₹64.6, and closed at ₹63.4.
This is a -1.86% slip from the previous day's closing price.
A total volume of 1,505 shares were traded at the close of the day’s session.
In the last one week, shares of Krebs Biochemicals & Industries Limited have slipped by -5.65%.
Krebs Biochemicals & Industries Limited's Key Ratios
Krebs Biochemicals & Industries Limited has a market cap of ₹1.75 billion, indicating a price to book ratio of 0 and a price to sales ratio of 5.0576.
In the last 12-months Krebs Biochemicals & Industries Limited’s revenue was ₹403.21 million with a gross profit of ₹948000 and an EBITDA of ₹0. The EBITDA ratio measures Krebs Biochemicals & Industries Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Krebs Biochemicals & Industries Limited’s operating margin was -55.68% while its return on assets stood at 0% with a return of equity of 0%.
In Q3, Krebs Biochemicals & Industries Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 148.2%.
Krebs Biochemicals & Industries Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-15.429 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Krebs Biochemicals & Industries Limited’s profitability.
Krebs Biochemicals & Industries Limited stock is trading at a EV to sales ratio of 7.359 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 5.0576.
Krebs Biochemicals & Industries Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.75 billion
- Total Liabilities
- ₹491.05 million
- Operating Cash Flow
- ₹-126450000.00
- Capital Expenditure
- ₹151.58 million
- Dividend Payout Ratio
- 0%
Krebs Biochemicals & Industries Limited ended 2024 with ₹1.75 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.75 billion while shareholder equity stood at ₹-994623000.00.
Krebs Biochemicals & Industries Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹491.05 million in other current liabilities, 215606000.00 in common stock, ₹-1210229000.00 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹3.72 million. The company’s total short-term debt was ₹99,904,000 while long-term debt stood at ₹1.73 billion.
Krebs Biochemicals & Industries Limited’s total current assets stands at ₹160.61 million while long-term investments were ₹0 and short-term investments were ₹2.86 million. Its net receivables were ₹5.25 million compared to accounts payable of ₹0 and inventory worth ₹119.46 million.
In 2024, Krebs Biochemicals & Industries Limited's operating cash flow was ₹-126450000.00 while its capital expenditure stood at ₹151.58 million.
Comparatively, Krebs Biochemicals & Industries Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹63.4
- 52-Week High
- ₹135
- 52-Week Low
- ₹51.1
- Analyst Target Price
- ₹
Krebs Biochemicals & Industries Limited stock is currently trading at ₹63.4 per share. It touched a 52-week high of ₹135 and a 52-week low of ₹135. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹70.26 and 200-day moving average was ₹81.02 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 8172.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Krebs Biochemicals & Industries Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was founded in 1991 and is headquartered in Hyderabad, India.